ABSTRACT The presence of mycotoxins in broiler feed can have deleterious effects on the wellbeing of the animals and their performance. Mycotoxin binders are feed additives that aim to adsorb mycotoxins in the intestinal tract and thereby prevent the oral absorption of the mycotoxin. The simultaneous administration of coccidiostats and/or antimicrobials with mycotoxin binders might lead to a reduced oral bioavailability of these veterinary medicinal products. This paper describes the influence of 3 mycotoxin binders (i.e., clay 1 containing montmorillonite, mica, and feldspars; clay 2 containing montmorillonite and quartz; and yeast 1 being a modified glucomannan fraction of inactivated yeast cells) and activated carbon on the oral bioavailability and pharmacokinetic parameters of the antimicrobials doxycycline and tylosin, and the coccidiostats diclazuril and salinomycin. A feeding study with 40 15 day-old broilers was performed evaluating the effects of long-term feeding 2 g mycotoxin binder/kg of feed. The birds were randomly divided into 5 groups of 8 birds each, i.e., a control group receiving no binder and 4 test groups receiving either clay 1, clay 2, yeast 1, or activated carbon mixed in the feed. After 15 d of feeding, both the control and each test group were administered doxycycline, tylosin, diclazuril, and salinomycin, consecutively, respecting a wash-out period of 2 to 3 d between each administration. The 4 medicinal products were dosed using a single bolus administration directly in the crop. After each bolus administration, blood was collected for plasma analysis and calculation of the main pharmacokinetic parameters and relative oral bioavailability (F = area under the plasma concentration-time curve (AUC 0-8 h ) in the test groups/AUC 0-8 h in the control group) * 100). No effects were observed of any of the mycotoxin binders on the relative oral bioavailability of the coccidiostats (i.e., F between 82 and 101% and 79 and 93% for diclazuril and salinomycin, respectively). Also, no significant effects could be noticed of any of the mycotoxin binders on the relative oral bioavailability of the antimicrobials doxycycline and tylosin (i.e., F between 67 and 83% and between 43 and 104%, respectively).
INTRODUCTION
Mycotoxins are secondary fungal metabolites frequently contaminating feed, which can be acutely toxic at high doses, whereas chronic exposure to lower contamination levels can result in poor animal performance and consequently economical damage (Binder, 2007) . It is estimated that in the United States Fusarium mycotoxins may cause damage equivalent to 20 million US dollars each year (Wu, 2007) . Because of a high prevalence of Fusarium mycotoxins in cereal based feed, pigs and poultry are frequently exposed to these toxins Streit et al., 2013) . Special feed additives, called mycotoxin detoxifiers, are frequently used in the pig and poultry industry to counter C 2017 Poultry Science Association Inc. Received August 2, 2016. Accepted December 18, 2016. 1 Corresponding author: siska.croubels@ugent.be the deleterious effects of mycotoxins (EFSA FEEDAP Panel, 2010) . Based on their mode of action, 2 categories can be distinguished, namely, mycotoxin modifiers and mycotoxin binders (Jard et al., 2011) . Mycotoxin modifiers aim to alter the chemical structure of the mycotoxin into chemical entities that are less or non-toxic. To date, all the modifiers available on the market are of microbiological origin and comprise extracted enzymes or whole cultures of yeasts or bacteria (European Commission, 2015) . Mycotoxin binders aim to form non-resorbable complexes with mycotoxins in the intestinal tract of the animal, making them unavailable for absorption. Most mycotoxin binders contain clay minerals but also yeast based products are often used. The clays used as mycotoxin binders are mostly smectites (De Mil et al., 2015b) , e.g., montmorillonites, which are the main constituents of bentonite. The maximum amount of bentonite allowed for aflatoxin B1 detoxification is 20 g/kg complete feed for ruminants, poultry, and pigs (European Commission, 2013a) ; however, the inclusion rate that is applied usually varies between one and 2.5 g/kg of complete feed. Total amounts of bentonite can reach levels higher than one to 2.5 g/kg because bentonite also can be used for other purposes such as pelletizing agents or to improve the rheological properties of feed (anticaking agent). The total amount of bentonite in complete feed is limited to 20 g/kg, with provision to indicate in the instructions for use that the simultaneous oral use with macrolides shall be avoided in any animal species, and that in poultry the simultaneous use with robenidine shall be avoided and the simultaneous use with other coccidiostats is contraindicated with a level of bentonite above 5 g/kg of complete feed (European Commission, 2013a) .
In addition to mycotoxin detoxifiers, coccidiostats and antimicrobials also can be mixed into the feed of broiler chickens, hence, antimicrobials/coccidiostats and mycotoxin binders may be simultaneously present in the intestinal tract and the mycotoxin binders might therefore interact with the oral absorption of antimicrobials/coccidiostats. A number of cases of such interactions have previously been described. In 1992, the Canadian Bureau of Veterinary Drugs reported a case of lack of efficacy of tylosin (TYL), a macrolide antimicrobial, in cattle fed a bentonite supplemented feed (Canadian Bureau of Veterinary Drugs, 1992). Next, a decreased efficacy of tilmicosin (TIL) against airsacculitis was demonstrated in chickens when 2% bentonite was included in the feed (Shryock et al., 1994) . Besides antimicrobials, coccidiostats also are mixed into the feed and may have beneficial effects on growth in addition to their anti-coccidial action (Elwinger et al., 1998; Hooge et al., 1999) . In 1998, Gray et al. demonstrated that bentonite reduced the efficacy of the coccidiostats monensin and salinomycin (SAL) in coccidiosis-infected broilers, but only when the coccidiostats were used below the recommended doses (Gray et al., 1998) . In 2010, the European Food Safety Authority (EFSA) stated that the safety of mycotoxin binders regarding nonspecific binding of oral veterinary drugs needs to be investigated (EFSA FEEDAP Panel, 2010) . Devreese et al. (2012) investigated the oral bioavailability and pharmacokinetics (PK) of TYL in fasted broilers after a single oral bolus administration of TYL or TYL together with bentonite (one g/kg feed). A relative oral bioavailability of 23.3% of TYL was observed in the test group receiving TYL together with bentonite (Devreese et al., 2012) . In 2015, De Mil et al. performed a similar study using doxycycline (DOX) and bentonite clays in fasted broilers (10 g/kg feed) and also observed a lower oral bioavailability (De Mil et al., 2015a) . This indicates that interactions between mycotoxin binders and coccidiostats and/or antimicrobials can occur, although further studies on this subject are limited. Moreover, the published PK studies exhibit important discrepancies with the field situation, such as solely acute or longterm exposure to the mycotoxin binder, absence of feed, or use of different inclusion rates.
This study aims to describe the influence of several mycotoxin binders on the oral bioavailability and PK properties of 2 antibiotics, TYL and DOX, and 2 coccidiostats, diclazuril (DIC) and SAL, in broiler chickens. Mycotoxin binders were mixed into the feed and fed for 2 wk, a setup that relates better to the field situation than previously described single bolus administration of binders in fasted broilers.
MATERIALS AND METHODS

Chemicals, Mycotoxin Binders, and Reagents
Activated carbon (Norit Carbomix R , AC) was purchased from Kela Pharma (Herentals, Belgium) and is used as a universal binding agent. Three mycotoxin binders were obtained from European wholesalers. The mycotoxin binders were labeled as clay 1, clay 2, and yeast 1. Clay 1 contained montmorillonite, mica, and feldspars, and had a d-spacing of 12.3·10
−10 m, a cation exchange capacity (CEC) of 7.0 cmol c /kg, a mineral fraction of 94.8% (m:m), and relative humidity of 5.2% (m:m). Clay 2 was a mixed layered montmorillonite and quartz, and had a d-spacing of 19.1·10
−10 m, a CEC of 51.0 cmol c /kg, a mineral fraction of 78.6% (m:m), and a relative humidity of 3.4% (m:m) (De Mil et al., 2015b) . Yeast 1 was a modified glucomannan fraction of inactivated yeast cells, and was classified as a binder.
DOX (Soludox 15% R , 150 mg doxycycline hyclate/g) was provided by Dechravet (Heusden-Zolder, Belgium), TYL (Tylan 100 Granules R , 100 mg tylosin phosphate/g) and DIC (Vecoxan R , 2.5 mg diclazuril/mL oral suspension) were purchased from Elanco Animal Health (Brussels, Belgium), and SAL (Sacox 120 R microGranulate, 120 mg salinomycine sodium/g) was kindly donated by Huvepharma (Antwerp, Belgium). Water, methanol (MeOH), and acetonitrile (ACN) used for the analytical experiments and preparation of stock solutions were of high-performance liquid chromatography (HPLC)-grade and purchased from Fisher Scientific (Wijnegem, Belgium).
Analytical standards of DOX, TYL, DIC, and SAL and the internal standards (IS) demethylchlortetracycline (DMCTC), valnemulin (VAL), methyldiclazuril (MeDIC), and nigericine (NIG) were purchased from Sigma-Aldrich (Bornem, Belgium). Stock solutions of 10 mg/mL were made in MeOH, which were stored at ≤ −15
• C. They were appropriately diluted in MeOH to obtain working solutions and stored at ≤ −15
• C. Trifluoroacetic acid (TFA) and hydrochloric acid (HCl) were purchased from Sigma-Aldrich.
Experimental Design
Forty 15 day-old straight-run broilers (Ross 308) were randomly divided into 5 groups of 8 animals, namely, one control group and 4 test groups. They were housed in concrete floor pens of 2 m 2 covered with wood shavings. The animals had ad libitum access to feed and drinking water. Temperature and relative humidity were controlled between 15 and 25 • C and 40 and 80%, respectively; the light regime was 6 h of darkness and 18 h of light. Housing conditions were in accordance to European guidelines regarding housing of experimental animals (European Commission, 2010). The feed was wheat-based commercially available feed. It was finely grinded and contained the following ingredients: wheat (59.49%), high protein soybean meal (17.70%), corn (8.00%), vegetable oil (5.80%), soy beans (5.00%), and premixed non-specified supplements (4.01%). The feed was analyzed for its mycotoxin content using a multi-mycotoxin LC-MS/MS method adapted from Monbaliu et al. (2009) . The method included deoxynivalenol (DON) and acetylated forms (3-and 15-acetylDON), zearalenone, aflatoxins (aflatoxins B 1 , B 2 , G 1 and G 2 ), sterigmatocystin, fumonisins (B 1 , B 2 and B 3 ), T 2 -toxin, HT 2 -toxin, ochratoxin A, fusarenon-X, nivalenol, diacetoxyscirpenol, neosolaniol, altenuene, alternariol, alternariol methyl ether, fumigaclavine, enniatine B1, paxilline, and roquefortine-C. Four test diets were prepared by supplementation of the feed with AC, clay 1, clay 2 or yeast 1 at the conventional dose of 2 kg per ton of feed (0.2%), respectively. This mixing was done manually according to geometrical mixing procedure as previously described (Earle and Earle, 1983) . The control (no binder) and test diets were fed to the control and test groups, respectively, for 15 days. Next, both the control and each test group were administered 4 veterinary medicinal products consecutively, respecting a wash-out period of 2 to 3 d between each administration. The 4 veterinary medicinal products were dosed using a single bolus administration directly in the crop. The following order was applied: DOX, TYL, DIC, and SAL. The night before each administration, 10 h of darkness was applied and one h before administration of the bolus, lights were turned on to ensure that the animals were in a fed state before administration of the antimicrobials or coccidiostats. The animals from the test groups also received a bolus containing the daily dose of binder; this was calculated using an average of 80 g feed intake per kg body weight (BW) each day. The animals from the control group received tap water. Immediately after the bolus containing the binder or water, a bolus containing the individual daily dose of veterinary medicinal product (DOX or TYL: both 20 mg/kg BW) or coccidiostat (DIC: 80 μg/kg BW or SAL: 4.8 mg/kg BW) was given to the animals. Blood samples were taken from the leg vein (vena metatarsalis plantaris superficialis) at zero h (just before administering the bolus), and one, 2, 3, 4, 6, and 8 h post administration (p.a.) for TYL and DOX. For DIC and SAL, samples were taken at zero, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 8 h p.a. Blood samples were collected in heparinized tubes, plasma was obtained by centrifugation, and samples were stored at ≤ −15
• C until analysis. The animal trial was not replicated. The birds were euthanized after the experiment by intravenously injecting a lethal dose of sodium pentobarbital (Kela Pharma). The complete trial was approved by the ethical committee of the Faculty of Veterinary Medicine and the Faculty of Bioscience Engineering of Ghent University (approval number: EC 2014/166).
Analytical Methods
DOX. An aliquot of 100 μL of plasma was supplemented with 50 μL of a working solution of the IS (10 μg/mL DMCTC) and thoroughly vortex mixed. Next, 15 μL of TFA and 50 μL of HPLC-grade water were added and the tube was vortex mixed. The sample was centrifuged for 10 min at 10,800 x g (Allegra X-15R centrifuge, Beckman Coulter; Suarlée, Belgium). Two-hundred μL of the supernatant was transferred to a glass vial and supplemented with 800 μL of HPLC-grade water, vortex mixed, and injected onto the HPLC-tandem mass spectrometry (MS/MS) system. The LC system consisted of a Waters 2695 quaternary solvent pump and autosampler (Waters, Milford, MA). The effluent was analyzed by the Quattro Ultima (Waters) MS/MS. The chromatographic conditions are presented in Supplementary Table 1 and  the MS parameters are displayed in Supplementary  Table 2. TYL. To 100 μL of plasma, 25 μL of a working solution of the IS (25 μg/mL VAL) was added. After vortex mixing, 100 μL of ACN were added and the sample was vortex mixed again before centrifugation as described above. The supernatant was filtered through a 0.2 μm Millex-GN nylon filter (Filter Service, Eupen, Belgium) into an autosampler vial for injection onto the LC-MS/MS system. The LC-MS/MS system was the same as described for DOX. The chromatographic conditions are presented in Supplementary Table 1 and the MS parameters are displayed in Supplementary Table 2.
DIC. An aliquot of 100 μL of plasma was spiked with 50 μL of the IS working solution (one μg/mL MeDIC). Next, 100 μL of a 0.5% HCl solution in ACN were added, followed by vortex mixing. Next, the samples were centrifuged as described above and the supernatant was filtered through a Millex-GV PVDF 0.22 μm filter (Filter Service) into an autosampler vial. The UPLC system consisted of an Acquity binary solvent manager (Waters) and an Acquity sample manager (Waters). The detector was a Quattro Premier XE (Waters) tandem MS. The chromatographic conditions are presented in Supplementary Table 1 and the MS parameters are displayed in Supplementary Table 2. SAL. An aliquot of 100 μL of plasma was supplemented with 25 μL of an IS working solution (20 μg/mL NIG). After vortex mixing, 100 μL of ACN were added and the sample was vortex mixed again before centrifugation as described above. The supernatant was filtered through a 0.2 μm Millex-GN nylon filter (Filter Service) into an autosampler vial and was injected onto the UPLC-MS/MS system. The UPLC system was the same as described for DIC. The chromatographic conditions are presented in Supplementary Table 1 and  the MS parameters are displayed in Supplementary  Table 2 .
Method Validation. The analytical methods were validated for both coccidiostats and both antimicrobials in plasma according to a validation protocol previously described by De Baere et al. (2011) using matrix-matched calibration curves. All parameters met the requirements and were in compliance with the recommendations and guidelines defined by the European Commission (European Commission, 2002a) and with international criteria described in the literature (Knecht and Stork, 1974; Heitzman, 1994; VICH, 2015) . The results of the validation procedure are presented in Supplementary Table 3 .
Pharmacokinetic and Statistical Analysis
Non-compartmental PK analysis was performed using WinNonlin R version 6.3 (Certara, St. Louis, MO) and following PK parameters were calculated: area under the plasma concentration-time curve from time zero to last sampling point and to infinity (AUC 0-8 h and AUC 0-inf , respectively), maximum plasma concentration (C max ), time to maximum plasma concentration (T max ), elimination rate constant (k el ), elimination half-life (T 1/2el ), volume of distribution scaled for the absolute oral bioavailability (V d /F), and total body clearance scaled for the absolute oral bioavailability (Cl/F). The relative oral bioavailability of DOX, TYL, DIC, and SAL (relative F) of the test groups was calculated as follows:
The effect of the different mycotoxin binders (AC, clay 1, clay 2, and yeast 1) on the PK parameters was assessed using a one-way analysis of variance (ANOVA) using SPSS v22 (IBM, Brussels, Belgium) with a Bonferroni-corrected LSD post-hoc test. Significance levels (p) below 0.05 were considered significant.
RESULTS AND DISCUSSION
The feed contained the following mycotoxins: nivalenol: 140 μg/kg, deoxynivalenol: 234 μg/kg, and zearalenone: 327 μg/kg. No other mycotoxins were detected above the limit of detection, as previously described (Monbaliu et al., 2009 ). The feed was compliant with the Directives and Recommendations of the European Commission for mycotoxins in broiler feed (European Commission, 2002b , 2013b . The plasma concentration-time profiles of DOX, TYL, DIC, and SAL are presented in Figure 1 . The PK parameters of all compounds are presented in Table 1 . Both in the control and test groups in general, a rather high variability on the results can be seen. This is probably due to the limited number of animals in each treatment group, although for pharmacokinetic studies in general, only one pen per treatment is used with 6 to 10 animals per group (Ismail and El-Kattan, 2004; Henri et al., 2012; Ji et al., 2014) .
The control group of DOX exhibits a mean C max and a mean AUC 0-inf , which are 45 and 70% lower, respectively, than previously reported for fasted broilers (De Mil et al., 2015a) . This is mainly attributed to the fed status of the birds in this study, as DOX may interact with fiber rich feed or bivalent cations such as Ca 2+ and Mg 2+ (Davis et al., 2006) , thereby reducing the oral absorption. On the other hand, the elimination parameters k el and T 1/2el are in the same range as previously described (Laczay et al., 2001; Ismail and El-Kattan, 2004; El-Gendi et al., 2010; De Mil et al., 2015a) . Since the discrepancy between AUC 0-inf and AUC 0-8 h exceeded 20%, only the AUC 0-8 h was taken into account for calculating the relative oral bioavailability (Toutain and Bousquet-Melou, 2004) . No differences in other PK parameters or in oral bioavailability between control and test groups could be noted. In the test groups, the relative oral bioavailability ranges from 66.9 up to 83.1%, yet the effect is not as pronounced as reported by De Mil et al. in fasted broilers (De Mil et al., 2015a) , in which relative oral bioavailabilities of 35.5 to 40.0% were reported for bentonite clays. Discrepancies with the latter study include amount of binder administered (10 g/kg feed vs. 2 g/kg feed in this study), type of mycotoxin binders studied, i.e., only clay 2 corresponds to montmorillonite 2 in a previously published paper (De Mil et al., 2015a) , duration of exposure to the mycotoxin binder prior to bolus administration of DOX (zero d vs. 15 d in this study), and feed status (fasted vs. non-fasted in this study). The present study more closely resembles the situation in practice, i.e., lower dose of binder, chronic exposure to the binder, and presence of feed in the intestinal tract. The absence of a strong influence of mycotoxin binders on the PK characteristics and oral bioavailability of DOX might mainly be explained by a lower dose, prandial state, and other composition of mycotoxin binders. The latter is partially negated by the results of an in vitro test reported previously (De Mil et al., 2015a) , which compared the binding potential of 7 mycotoxin binders, including bentonite-based mycotoxin binders, to DOX in an in vitro experiment. DOX (100 μg/mL) was incubated for 4 h at 37
• C with 20 mg of each of the 7 binders in 5 mL of phosphate buffered saline solution (PBS) at pH 2.5 and 6.5. All samples expressed a binding between 80 and 100% of the added DOX. This indicates the presence of feed and the amount of binder relative to the amount of DOX are important variables that determine possible binding of the drug. In a study in which the effect of mycotoxin binders on the oral bioavailability of DOX was studied in pigs, an effect was seen in the groups that were fasted and received Broiler chickens of the test groups were fed for 2 wk with feed supplemented with 0.2% of one of the mycotoxin binders: activated carbon (AC), clay 1, clay 2, or yeast 1. The control group received no binder. Next, the control and test groups received an oral bolus containing water or the daily dose of mycotoxin binder, respectively, immediately followed by a bolus containing the daily dose of DOX, TYL, DIC, or SAL for both the control group and test groups, at the recommended daily dose. Results are presented as mean + or − SD (n = 8).
a single dose of mycotoxin binder of 10 g/kg feed. The effect diminished when a lower dose of binder was used (2 g/kg feed). No effect at all was seen when the animals were fed and the dose was mixed into the feed at 2 g/kg feed; these conditions correspond with field conditions (De Mil et al., 2016) .
The PK values of TYL of the control group are in accordance with previously reported values in non-fasted animals (Lacoste, 2003) , but were lower than reported in studies that used fasted animals (Devreese et al., 2012; Ji et al., 2014) . Although the average C max and AUC 0-inf in the clay 1, clay 2, and yeast 1 group tend to be lower, no significant differences were demonstrated. Significant differences for T 1/2el and V d /F were noted for the yeast 1 group when compared to the control group, while Cl/F of the clay 1 group differed significantly from the control group, although large interanimal variability can be seen. The reason for these differences remains to be elucidated. The influence between mycotoxin binders and TYL is not as pronounced as previously described (Devreese et al., 2012) , in which a relative F of 23.3% was seen compared to a relative F of 42.8% and higher in this study. The main differences between both studies are again the feed status of the animals (fasted and non-fasted, respectively), the type of mycotoxin binder, dose of mycotoxin binder used (one g/kg feed vs. 2 g/kg feed in this study), duration of exposure to mycotoxin binder (zero d vs. 15 d in this study), and salt-form of TYL (tartrate vs. phosphate in this study). The lower plasma concentrations in the control group can be partially attributed to the use of the phosphate salt instead of the tartrate salt of TYL, which have different oral F, i.e. 13.7% for the phosphate salt and 27.0% for the tartrate salt (Ji et al., 2014) . Again, the main factor that can explain both the lower concentrations in the control group and the diminished influence between the mycotoxin binders and TYL is the prandial status.
The absorption of DIC is slow in general, reaching mean levels of 14.57 ± 3.23 ng/mL (mean ± SD, n = 8) in the control group after 6 to 8 hours. Only AUC 0-8 h , C max , and T max could be calculated for DIC. The values of the PK parameters of DIC and SAL obtained in this study are consistent with the few reports available describing the PK of these coccidiostats in fed birds (European Commission, 1991; Henri et al., 2012; European Broiler chickens of the test groups were fed for 2 wk with feed supplemented with 0.2% of one of the mycotoxin binders: activated carbon (AC), clay 1, clay 2, or yeast 1. The control group received no binder. Next, the control and test groups received an oral bolus containing water or the daily dose of mycotoxin binder, respectively, immediately followed by a bolus containing the daily dose of DOX, TYL, DIC, or SAL for both the control group and test groups, at the recommended daily dose. AUC: area under the plasma concentration-time curve from time zero to 8 h or zero to infinity; Relative F: (area under the plasma concentration-time curve (AUC 0-8 h ) in the test group/AUC 0-8 h in the control group) * 100; T max : time of maximum plasma concentration; C max : maximum plasma concentration; k el : elimination rate constant; T 1/2el : elimination half-life; V d /F: volume of distribution scaled to the absolute bioavailability; Cl/F: total body clearance scaled to the absolute bioavailability; * significant differences compared to the control group (P ≤ 0.05).
Medicines Agency, 2013). For DIC and SAL, no differences in AUC 0-8 h , relative F, T max , or C max were seen among the different treatment groups, indicating that the mycotoxin binders have no effect on the absorption of the coccidiostats. To date, EU regulations prohibit the simultaneous use of coccidiostats other than robinidine and bentonite clay when the clay is used at an inclusion rate higher or equal to 5 g/kg feed. In our study, 2 g/kg feed was included and no effects were observed, which corresponds well with these EU regulations.
In previous studies in which effects were reported with respect to oral bioavailability and PK parameters of TYL and DOX (Devreese et al., 2012; De Mil et al., 2015a) , an oral bolus model with fasted chickens was used. The conditions in those reports can be considered as a worst-case scenario in which only medicinal product and binders were present in the intestinal tract after the boli were administered. Therefore, only the direct binding effect of the mycotoxin binders was evaluated without the effect of feed. This approach is suitable when screening for effects but shows discrepancies with the field situation regarding the duration of exposure to mycotoxin binder and the presence of feed. The setup used in this study is similar to the reported bolus studies; however, it includes the long-term effects of mycotoxin binder and the presence of feed. In field conditions, the amount of feed relative to the amount of binder and medicinal product will be higher; hence, this model can be considered as a more reliable approximation of field conditions for investigating the safety of mycotoxin binders.
It can be concluded that no significant effects were observed of any of the mycotoxin binders on the PK and oral bioavailability of the coccidiostats and antimicrobials studied. Based on these results and literature, both dose of mycotoxin binders as well as prandial status are important variables decisive for effect of mycotoxin binders on the PK and oral bioavailability of oral veterinary medicinal products.
SUPPLEMENTARY DATA
Supplementary data are available at PSCIEN online. Table S1 . Chromatographic conditions for the analysis of doxycycline (DOX), tylosin (TYL), diclazuril (DIC), and salinomycin (SAL) in broiler plasma. Table S2 . Mass spectrometric parameters for the analysis of doxycycline (DOX), tylosin (TYL), diclazuril (DIC), and salinomycin (SAL) in broiler plasma. Table S3 . Validation parameters for the analytical methods for doxycycline (DOX), tylosin (TYL), salinomycin (SAL), and diclazuril (DIC) in broiler plasma.
